Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Denosumab Fracture Data Positive In Prostate Cancer Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.

You may also be interested in...

Aranesp Takes A Punch; Sales Plummet 25 Percent In Fourth Quarter 2007

With ESA safety in the spotlight, Amgen faced its toughest year, CEO Sharer says.

Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio

Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.

Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts